The short version of wound model fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-08-18 and is reviewed periodically as new material appears.
Thymosin beta-4 was isolated from calf thymus in the early 1980s and later characterised as an abundant intracellular actin-sequestering protein. Interest in short synthetic fragments grew once the actin-binding motif had been mapped to the middle of the sequence. TB-500 came out of that line of work as a truncated analogue rather than a natural isolate, and it is now sold mainly to laboratories. Published studies on the fragment have been largely in vitro or in animal models, and controlled human trials remain sparse, so claims about effects in people rest on extrapolation.
Literature and online discussion often conflate TB-500 with full-length thymosin beta-4, even though the two differ in size and are not interchangeable in analytical terms. The fragment is produced by solid-phase peptide synthesis, and the product is a defined seven-residue chain rather than a biological extract. Because the term is a trade-style label, two vendors may supply materials of the same nominal sequence but different counter-ion content, purity, or water content. Comparisons across studies are therefore difficult unless the exact sequence and purity are reported.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Supplied as a lyophilised cake in sealed vials |
| Solubility class | Freely soluble in water | Polar and charged side chains dominate the sequence |
| Typical storage temperature | -20 °C or below | Dry and dark; a desiccant is often recommended |
| Identity confirmation | Mass spectrometry | Observed mass compared with the theoretical value |
| Common synonyms | Thymosin beta-4 fragment | Also written as T beta 4 fragment 17-23 |
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Thymosin beta-4 is a naturally occurring protein of 43 amino acids found in most mammalian cells, where it binds actin monomers and influences filament dynamics. It was first isolated from thymus tissue in the early 1980s, and its actin-binding activity was later mapped to a short region near the N-terminus. The synthetic fragment sold as TB-500 was designed to reproduce that region rather than the full protein. Whether a short fragment reproduces the behavior of the intact molecule remains an open question, since the parent protein carries additional structural elements outside the binding region.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
A gas panel or gas manifold is the control equipment for supplying the breathing gas to the divers. Primary and reserve gas is supplied to the panel through shutoff valves from a low-pressure compressor or high-pressure storage cylinders ("bombs", "bundles", "quads", or "kellys"). The gas pressure may be controlled at the panel by an industrial pressure regulator, or it may already be regulated closer to the source (at the compressor, or at the storage cylinder outlet). The supply gas pressure is monitored on a gauge at the panel, and an over-pressure valve is fitted in case the supply pressure is too high. The gas panel may be operated by the diving supervisor if the breathing gas is air or a fixed ratio premix, but if the composition must be controlled or monitored during the dive it is usual for a dedicated gas panel operator, or "gas man" to do this work. There is a set of valves and gauges for each diver to be supplied from the panel. These include:
== Development == The CPT was originally built for the Tandem Accelerator Superconducting Cyclotron (TASCC) facility at Chalk River Laboratories in Chalk River, Ontario, Canada. However, it was transferred to Argonne National Laboratory when the TASCC accelerator was decommissioned in 1998 due to funding issues. The CPT spectrometer is designed to provide high-precision mass measurements of short-lived isotopes using radio-frequency (RF) fields. Accurate mass measurements of particular isotopes such as selenium-68 are important in the understanding of the detailed reaction mechanisms involved in the rapid-proton capture process, which occurs in astrophysical events like supernovae explosions and X-ray bursts. An X-ray burst is one possible site for the rp-process mechanism which involves the accretion of hydrogen and helium from one star onto the surface of its neutron star binary companion. Mass measurements are required as key inputs to network calculations used to describe this process in terms of the abundances of the nuclides produced, the light-curve profile of the X-ray bursts, and the energy produced. In the current configuration, more than 100 radioactive isotopes have been measured with half-lives much less than a second and with a precision (Δm/m) approaching 10−9. Recently, a novel injection system, the RF gas cooler, has been installed on the CPT to allow fast reaction products to be decelerated, thermalized and bunched for rapid and efficient injection.
A review of lichen taxonomic literature from 2018 to 2020 found that of over 700 new species published, only 39% included any DNA sequences. The most commonly used gene was the ITS (present in roughly 82% of those that had molecular data), while only about 10% of new species were supported by three or more genes. These figures show that while multilocus sequencing underpins higher-level systematics, species-level descriptions (alpha taxonomy) often remain constrained by practical limits on sequencing or by the sufficiency of morphological evidence. Sanger-era phylogenetics laid the groundwork for later genomic studies. By the late 2000s lichenologists had a working framework for most major lineages and clearer criteria for natural versus artificial groups. The framework relied on what now seem small datasets—only a few kilobases per species—yet these sequences resolved many relationships. Although some 2010-era authors questioned the value of small multigene matrices, Lücking (2020) contends that sound sampling and analysis can outweigh sheer data volume. By the early 2020s, many new species—even some higher taxa—are still described from a few gene regions plus morphology, a practise that remains practical where large-scale sequencing is not yet feasible. The Sanger era showed that modest molecular datasets could overturn classifications—splitting some genera, merging others—and it supplied a scaffold for later genome-scale studies.
Sources: en.wikipedia.org
=== Military contact between Poznan and Warsaw === Throughout the month of November, the Polish army sought to recruit Poles from the region into its military. At the same time, they also held talks with Poznan to organize proper relations between Poznan and Warsaw and to prepare for an armed uprising. Jozef Pilsudski and his government did not intend to enter armed conflict with Germany, this being a major point of disagreement between the two groups, and did not believe any attempts at armed rebellion would work, convinced that only the Entente could grant Poland this region. However, he included it in his plans to rebuild the country and treated it as a part of Poland, it being historically Polish. On 28 October 1918, Major Włodzimierz Zagórski, as Deputy Head of the General Staff of the Polish Armed Forces, established a dedicated command in Kalisz wherein a department of affairs related to Greater Poland was set up. A military regiment was set up in Ostrow, the city being held by the Ostrow People's Council, however it was soon after dissolved and its members were sent to Kalisz. To the dismay of the Poles, the Ostrow People's Council addressed a letter to the Supreme Command in Kalisz, renouncing military cooperation, claiming that it only recognises the Commissariat of the Supreme People's Council on 17 November. Nevertheless, the Poznan Central Citizens' Committee delegated Celestyn Rydlewski to visit the Polish General Staff. He suggested conscripting Polish citizens of the Prussian Partition into the Polish Armed Forces.
==== Steatosis ==== Hepatotoxicity may manifest as triglyceride accumulation, which leads to either small-droplet (microvesicular) or large-droplet (macrovesicular) fatty liver. There is a separate type of steatosis by which phospholipid accumulation leads to a pattern similar to the diseases with inherited phospholipid metabolism defects (e.g., Tay–Sachs disease)
The draw took place on December 5, 2025, at the Kennedy Center in Washington, D.C. The draw ceremony began with FIFA presenting the first FIFA Peace Prize to Donald Trump, an award which fueled scrutiny and ridicule among human rights groups, analysts, and others. The 48 teams were divided into four pots of 12. Pot 1 consisted of the three hosts and the top nine teams from the November 2025 FIFA Men's World Ranking. Pots 2, 3, and 4 consisted of the remaining teams according to the ranking. The four winners of the UEFA playoffs and the two winners of the inter-confederation playoffs were not known at the time of the draw and thus were automatically allocated to Pot 4. The 12 groups were randomly formed by selecting one team from each of the four pots. With the exception of UEFA, no group could have more than one team from the same confederation drawn into it. The three host nations were pre-allocated to three groups for scheduling purposes. Mexico was placed in Group A, Canada in Group B, and the United States in Group D. The confederation restriction applied to all three potential winners of the inter-confederation playoffs. FIFA also announced that, "in the interest of ensuring competitive balance", the teams ranked first (Spain), second (Argentina), third (France), and fourth (England) would be drawn into opposite pathways. Therefore, should these teams win their groups, they would be unable to meet until the semifinals, and the first and second ranked teams would be unable to meet until the final.
Joseph Stewart Fruton (May 14, 1912 – July 29, 2007), born Joseph Fruchtgarten, was a Polish-American biochemist and historian of science. His most significant scientific work involved synthetic peptides and their interactions with proteases; with his wife Sofia Simmonds he also published an influential textbook, General Biochemistry (1953; 1958). From 1970 until his death, Fruton worked extensively on the history of science, particularly the history of biochemistry and molecular biology.
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 matches only residues 17 to 23 of that chain. The two are related but differ in size, and a method that identifies one does not automatically identify the other.
It corresponds to the actin-binding region of thymosin beta-4. Commercial synthesis reproduces that seven-residue stretch, usually with an acetyl group on the N-terminus.
It is not authorised as a medicine in the United States or the European Union and is distributed as a research chemical. Labels consequently carry research-use-only statements rather than clinical indications.
The leading proposal involves sequestration of monomeric actin, which would alter cytoskeletal turnover and cell movement. The actin-binding motif shared with the parent protein is central to that idea. Direct confirmation in whole organisms remains limited.